Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4.99M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
65.7M
-
Shares change
-
-1.04M
-
Total reported value, excl. options
-
$1.75B
-
Value change
-
+$31.2M
-
Put/Call ratio
-
0.39
-
Number of buys
-
77
-
Number of sells
-
-59
-
Price
-
$26.61
Significant Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q4 2020
173 filings reported holding MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2020.
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.7M shares
.
Largest 10 shareholders include BlackRock Inc. (7.99M shares), Avoro Capital Advisors LLC (6.8M shares), WELLINGTON MANAGEMENT GROUP LLP (4.65M shares), Bain Capital Life Sciences Investors, LLC (3.45M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.3M shares), STATE STREET CORP (3.15M shares), VANGUARD GROUP INC (3.07M shares), Sarissa Capital Management LP (2.93M shares), Rock Springs Capital Management LP (2.06M shares), and CITADEL ADVISORS LLC (1.96M shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.